A team from KTH Royal Institute of Technology’s(SciLifeLab) research center and Gothenburg University employed the biological networks generated for 46 major human tissues in order to identify the liver-specific gene targets.
The results were published in
The researchers mapped the metabolic changes caused by accumulated fat in liver cells, and combined this data with an analysis of biological networks of liver and other human tissues. Doing so enabled them to identify the liver-specific drug targets whose inhibition will not cause any side effect to other human tissues, says lead author, a SciLifeLab fellow, who had earlier established a connection between NAFLD and HCC and increased fat synthesis in liver tissue.
One of the most common chronic liver problems in the world, hepatic steatosis is the excessive accumulation of fat in the liver and a key characteristic of non-alcoholic fatty liver disease (NAFLD). The disease is the consequence of obesity, diabetes, or excessive alcohol intake and can lead to non-alcoholic steatohepatitis (NASH), cirrhosis, liver cancer and even hepatic failure. There are few treatments, even though the need is urgent.
Mardinoglu says the team’s network modeling approach can be used in the identification of drug targets and eventually in the development of efficient strategies for treating a number of chronic liver diseases.
The work relied on data from the KTH, and The Genotype-Tissue Expression (GTEx) project consortium. To validate their computer modeling predictions, researchers performed experiments in human cancer cell lines, mouse liver samples and primary human hepatocytes, demonstrating functional relationships between the liver genes. Mardinoglu says they showed that the inhibition of these genes decreases cell growth and liver fat content., a consortium involving
The researchers identified liver-specific genes linked to NAFLD pathogenesis, such as pyruvate kinase liver and red blood cell, (PKLR), or to HCC pathogenesis, such as PKLR, patatin-like phospholipase domain containing 3 (PNPLA3) and proprotein convertase subtilisin/kexin type 9 (PCSK9), all of which are potential targets for drug development.
Mathias Uhlen, director of the Human Protein Atlas project and co-author of the paper, says: “I am extremely pleased that the resource created through the Human Protein Atlas effort has been used in the analysis of clinical data obtained from liver disease patients and that this analysis has led to the identification of liver-specific drug targets that can be used for treatment of this clinically important patient group.”
The study was funded by the
Source : KTH Royal Institute of Technology